Epicardial adiposity as a predictor of COVID-19 severity in overweight and obese patients
https://doi.org/10.15829/1560-4071-2022-4850
Abstract
Aim. To evaluate epicardial adiposity (EA), verified on the basis of epicardial adipose tissue (EAT) thickness according to echocardiography, as a possible predictor of the severity of coronavirus disease 2019 (COVID-19) course in overweight and obese patients in a retrospective analysis of data.
Material and methods. We analyzed data on 165 patients (age, 45,2±4,7 years; men, 67,9%; body mass index, 31,4±3,5 kg/m2) who received outpatient or inpatient treatment for symptomatic COVID-19 in period from March 2020 to November 2021. Patients with diabetes, stage III-V chronic kidney disease and/ or cardiovascular disease were excluded from the analysis, with the exception of hypertension. EA was verified in the case of EAT thickness ≥4,8 mm for persons aged 35-45 years and ≥5,8 mm for persons 46-55 years old.
Results. Patients with EA were characterized by higher hospitalization rates (52,2% vs 9,0%, p<0,01), moderate (56,5% vs 19,7%, p<0,01), high and very high severity (17,4% vs 3,3%, p<0,01) of disease course, lung injury of CT-1, CT-2 and CT-3 (32,6% vs 9,8% (p<0,01), 21,7% vs 7,4% (p<0,05), and 15,2% vs 2,5% (p<0,01), respectively), invasive ventilation (8,7% vs 0,8%, p<0,05) and C-reactive protein >10 mg/l (69,6% vs 21,3%, p<0,01). Predictors of hospitalization for symptomatic COVID-19 according to multivariate logistic regression analysis were age, fasting glycemia, systolic blood pressure, EAT thickness, which was characterized by the highest standardized regression coefficient among other predictors (0,384, p<0,001).
Conclusion. EAT thickness may be one of the predictors of COVID-19 severity in overweight and obese patients. Persons with EA in the case of COVID-19 need more careful monitoring and measures to prevent severe course and complications.
About the Authors
M. A. Druzhilov
Petrozavodsk State University
Russian Federation
Russian Federation
Petrozavodsk
T. Yu. Kuznetsova
Petrozavodsk State University
Russian Federation
Russian Federation
Petrozavodsk
References
1. NCD Risk Factor Collaboration. Trends in adult body mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 128.9 million participants. Lancet. 2016;387(10026):1377-96. doi:10.1016/S0140-6736(16)30054-X.
2. Dalamaga M, Christodoulatos G, Karampela I, et al. Understanding the Co-Epidemic of Obesity and COVID-19: Current Evidence, Comparison with Previous Epidemics, Mechanisms, and Preventive and Therapeutic Perspectives. Current Obesity Reports. 2021;10(3):214-43. doi:10.1007/s13679-021-00436-y.
3. Gkogkou E, Barnasas G, Vougas K, Trougakos I. Expression profiling meta-analysis of ACE2 and TMPRSS2, the putative anti-inflammatory receptor and priming protease of SARS-CoV-2 in human cells, and identification of putative modulators. Redox Biol. 2020;36:101615. doi:10.1016/j.redox.2020.101615.
4. Watanabe M, Balena A, Tuccinardi D, et al. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine. Diabetes Metab Res Rev. 2022;38(1):e3465. doi:10.1002/dmrr.3465.
5. Gao F, Zheng K, Wang X, et al. Obesity is a risk factor for greater COVID-19 severity. Diabetes Care. 2020;43(7):72-4. doi:10.2337/dc20-0682.
6. Lighter J, Phillips M, Hochman S, et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin Infect Dis. 2020;71(15):896-7. doi:10.1093/cid/ciaa415.
7. Druzhilov MA, Kuznetsova ТY. Heterogeneity of obesity phenotypes in relation to cardiovascular risk. Cardiovascular Therapy and Prevention. 2019;18(1):161-7. (In Russ.) doi:10.15829/1728-8800-2019-1-162-168.
8. Watanabe M, Caruso D, Tuccinardi D, et al. Visceral fat shows the strongest association with the need of intensive care in patients with COVID-19. Metabolism. 2020;111:154319. doi:10.1016/j.metabol.2020.154319.
9. Favre G, Legueult K, Pradier C, et al. Visceral fat is associated to the severity of COVID-19. Metabolism. 2021;115:154440. doi:10.1016/j.metabol.2020.154440.
10. Grodecki K, Lin A, Razipour A, et al. Epicardial Adipose Tissue Is Associated With Extent of Pneumonia and Adverse Outcomes in Patients With COVID-19. Metabolism. 2021;115:154436. doi:10.1016/j.metabol.2020.154436.
11. Bihan H, Heidar R, Beloeuvre A, et al. Epicardial adipose tissue and severe Coronavirus Disease 19. Cardiovasc Diabetol. 2021;20(1):147. doi:10.1186/s12933-021-01329-z.
12. Mehta R, Bello-Chavolla O, Mancillas-Adame L, et al. Epicardial adipose tissue thickness is associated with increased COVID-19 severity and mortality. Int J Obes. 2022;11:1-8. doi:10.1038/s41366-021-01050-7.
13. Kuznetsova TY, Chumakova GA, Druzhilov MA, et al. Clinical application of quantitative echocardiographic assessment of epicardial fat tissue in obesity. Russian Journal of Cardiology. 2017;(4):81-7. (In Russ.) doi:10.15829/1560-4071-2017-4-81-87.
14. Zhao L. Obesity Accompanying COVID-19: The Role of Epicardial Fat. Obesity. 2020;28(8):1367. doi:10.1002/oby.22867.
15. Lasbleiz A, Gaborit B, Soghomonian A, et al. COVID-19 and Obesity: Role of Ectopic Visceral and Epicardial Adipose Tissues in Myocardial Injury. Front Endocrinol. 2021;12:726967. doi:10.3389/fendo.2021.726967.
Supplementary files
Review
For citations:
Druzhilov M.A., Kuznetsova T.Yu. Epicardial adiposity as a predictor of COVID-19 severity in overweight and obese patients. Russian Journal of Cardiology. 2022;27(3):4850. (In Russ.) https://doi.org/10.15829/1560-4071-2022-4850
Views:
656
Email this article 